Monoclonal Antibodies for High-Risk, COVID-19-Positive Patients
Sep 30, 2021 09:31AM ● By Courtesy of Combat COVID
If you’ve tested positive for COVID-19, one of the first
questions you may have is, What can I do to reduce the risk of getting sicker?
The good news is, there are treatments that may reduce that risk. Depending on
your age, health history, and how long you’ve had symptoms of COVID-19, you may
qualify for a promising form of treatment for the disease. It’s called monoclonal
antibody (mAb) treatment.
Some early
evidence suggests that mAb treatment can reduce the amount of the SARS-CoV-2
virus in a person's system. This amount is known as viral load. Having a lower
viral load means you may have milder symptoms thereby decreasing the likelihood
of you needing to stay in the hospital.
The FDA has
issued Emergency Use Authorization for two investigational monoclonal antibody
treatments that can attach to SARS-CoV-2, the coronavirus that causes COVID-19.
These antibodies could help your immune system recognize and respond more
effectively to the virus.
These
treatments have been authorized for patients with mild to moderate
cases. This includes those who have had symptoms for 10 days or less,
who are 12 years of age
and older, and who are at high risk for progressing to severe COVID-19
and/or
hospitalization. It also includes people who are 65 years old or older,
and for
people who have certain chronic medical conditions.
There is no cost for the antibodies themselves, but the facility may charge for the
infusion (giving the treatment by IV). Medicare covers the IV treatment costs,
but Medicaid coverage is different in each state. Many large private insurance
plans cover all costs, but you should check with yours to find out for sure. If
you do not have insurance, ask the treatment facility if there are any fees.
Your body
naturally makes antibodies to fight
infection. However, your body may not have
antibodies designed to recognize a novel (or new) virus like SARS-CoV-2,
the virus that causes COVID-19. Monoclonal
antibodies, or mAbs, are made in a laboratory to fight a particular
infection—in this case, SARS-CoV-2—and are given to patients directly with an
infusion. That’s why mAb treatment may help patients who are at high risk for
serious symptoms or having to stay in the hospital.
mAb treatment for COVID-19 is
different from a COVID-19 vaccine. A vaccine triggers your body’s natural
immune response, but can take weeks to develop enough antibodies and prevent
some kinds of infection. Some vaccines for COVID-19 require two shots, so your
body can develop its own immune response
to the disease. But if you already have the
virus, mAb treatment gives your body the antibodies it needs to protect itself.
Combat COVID is a one-stop resource created by the U.S.
Department of Health and Human Services.